Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LATE-REC-SURF Trial
2019-004720-38Phase 2Terminated
- Sponsor
- Policlinico Gemelli
- Start
- Oct 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of Poractant alfa in respiratory distress syndrome (RDS) and respiratory failure of prematurity (RFP) (2 arms), sponsored by Policlinico Gemelli. Primary endpoint: First successful extubation. Started Oct 2020; status: terminated.
02
Drugs
Poractant alfa
03
Conditions
respiratory distress syndrome (RDS)respiratory failure of prematurity (RFP)
Beyond the preview
Go deeper on 2019-004720-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004720-38.